A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

What Was Tested

In this phase 3 trial, researchers set out to test Semaglutide.

It had three arms (groups): Zenagamtide (experimental), one (active comparator) and one (active comparator).

The registry classes the interventions as drug.

Who Took Part

650 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Male or female (sex at birth). Age 18 years or above at the time of signing the informed consent.

The full record lists 2 inclusion and 3 exclusion criteria; among the exclusions: history of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records.

How the Study Was Run

Design: randomized, parallel-group and quadruple-blind.

The participants were allocated by chance, so the Semaglutide group and the comparison group should start out alike.

The Semaglutide group and the comparison group ran side by side rather than switching.

Neither the participants nor the staff measuring them knew who was on Semaglutide, so expectations could not easily colour the readings.

Those kept unaware of assignments: participant, care provider, investigator and outcomes assessor.

It started in 2026-09-22 with completion listed for 2028-10-10.

It ran at 45 sites in United States (45).

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Relative change in body weight (time frame: From week 0 to week 84).

It also tracked 1 secondary outcome, for example Change in waist circumference.

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Semaglutide in 650 people.

With 650 participants it is a large trial for this field.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.